Stocktoria
Monte Rosa Therapeutics, Inc. GLUE
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-24
Monte Rosa Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | — | — | — |
| R&D expense | $141.5M | $121.6M | $111.3M | $85.1M | $57.2M | $24.0M |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M | -$28.0M |
| Income tax | -$1.1M | $2.6M | $338,000 | $0 | — | — |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M | -$35.9M |
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M | -$23.1M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M | -$26.4M |
| Cash & equivalents | $129.9M | $224.3M | $128.1M | $54.9M | $346.1M | $41.7M |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M | $49.4M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M | $30.3M |
| Shareholders' equity | $233.1M | $222.9M | $179.2M | $271.4M | $347.5M | -$48.7M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +63.5% | — | — | — | — | — |
| Free cash flow growth | -172.3% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.